TickerFacts.

Lexeo Therapeutics, Inc. (LXEO): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$108.99M
Year ended 2025-12-31
-$94.82M
Trailing 12 months to 2026-06-30
2022-12-31: -$60.39M2023-12-31: -$68.24M2024-12-31: -$105.46M2025-12-31: -$108.99M-$108.99M
2022-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$108.99Mn/m2026-03-30, From 2025-01-01
2024-12-31-$105.46Mn/m2026-03-30, From 2024-01-01
2023-12-31-$68.24Mn/m2025-03-24, From 2023-01-01
2022-12-31-$60.39Mn/a2024-03-11, From 2022-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Lexeo Therapeutics, Inc. (LXEO)2025-12-31-$108.99Mn/m
Tectonic Therapeutic, Inc. (TECX)2025-12-31-$82.66Mn/m
Coherus Oncology, Inc. (CHRS)2025-12-31-$177.21Mn/m
X4 Pharmaceuticals, Inc (XFOR)2025-12-31-$85.61Mn/m
Alector, Inc. (ALEC)2025-12-31-$150.29Mn/m
Kyverna Therapeutics, Inc. (KYTX)2025-12-31-$168.03Mn/m
MeiraGTx Holdings plc (MGTX)2025-12-31-$93.43Mn/m
LENZ Therapeutics, Inc. (LENZ)2025-12-31-$90.85Mn/m
DBV Technologies S.A. (DBVT)2025-12-31-$144.07Mn/m

Compare LXEO, TECX, CHRS, XFOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗